How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review
出版年份 2023 全文链接
标题
How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review
作者
关键词
-
出版物
Trials
Volume 24, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-11-06
DOI
10.1186/s13063-023-07730-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
- (2023) Timothée Olivier et al. BMC CANCER
- Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain
- (2021) Celine Yeh et al. SEMINARS IN ONCOLOGY
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J. Page et al. Systematic Reviews
- Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial
- (2021) Supriya Chopra et al. JOURNAL OF CLINICAL ONCOLOGY
- Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
- (2021) Anna-Maria Fontrier et al. Pharmacoeconomics-Open
- A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology
- (2020) Holly Cranmer et al. JOURNAL OF MEDICAL ECONOMICS
- Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
- (2020) Hao Chen et al. Translational Lung Cancer Research
- The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial
- (2019) Carrie Anne Minnaar et al. PLoS One
- Proposals on Kaplan–Meier plots in medical research and a survey of stakeholder views: KMunicate
- (2019) Tim P Morris et al. BMJ Open
- Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
- (2019) Andrew R Clamp et al. LANCET
- Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology
- (2018) Matthieu Texier et al. Computational and Mathematical Methods in Medicine
- First-line treatment in metastatic colorectal cancer: Important or crucial?
- (2017) David Malka et al. EUROPEAN JOURNAL OF CANCER
- Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework
- (2017) Shogo Nomura et al. Journal of Biopharmaceutical Statistics
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Checkpoint inhibition: new treatment options in urologic cancer
- (2017) Daan Joost De Maeseneer et al. ACTA CLINICA BELGICA
- Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting
- (2016) Alona Zer et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
- (2016) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis
- (2016) Sarah Batson et al. PLoS One
- Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
- (2016) Anna Miquel-Cases et al. PLoS One
- Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis
- (2015) Emilio Bria et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
- (2015) Ian H Kunkler et al. LANCET ONCOLOGY
- Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy
- (2015) Xiaofei Bai et al. PHARMACEUTICAL STATISTICS
- Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
- (2014) Ursula A. Matulonis et al. CANCER
- Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials
- (2014) Xabier García-Albéniz et al. INTERNATIONAL JOURNAL OF CANCER
- Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
- (2014) Ajay Vora et al. LANCET ONCOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial
- (2013) J. Pénichoux et al. EUROPEAN JOURNAL OF CANCER
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
- (2013) Martin Hoyle et al. VALUE IN HEALTH
- Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
- (2012) Nicholas D James et al. LANCET ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
- (2011) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09
- (2010) Anthony L. Zietman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started